TrialJapanese journal of clinical oncology2018

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

Katsuyuki Kiura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.